Efficacy and tolerance of osilodrostat in patients with severe Cushing’s syndrome due to non-pituitary cancers

in European Journal of Endocrinology
View More View Less
  • 1 Department of Endocrinology, Diabetes and Nutrition, Hôpital Haut Lévêque, CHU and University of Bordeaux, Pessac, France

Correspondence should be addressed to A Tabarin; Email: antoine.tabarin@chu-bordeaux.fr
Restricted access

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 311 311 311
Full Text Views 50 50 50
PDF Downloads 38 38 38
  • 1

    Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A. MANAGEMENT OF ENDOCRINE DISEASE: Cushing’s syndrome due to ectopic ACTH secretion: an expert operational opinion. European Journal of Endocrinology 2020 182 R29R58. (https://doi.org/10.1530/EJE-19-0877)

    • Search Google Scholar
    • Export Citation
  • 2

    Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A & Endocrine Society. Treatment of Cushing’s syndrome: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2015 100 28072831. (https://doi.org/10.1210/jc.2015-1818)

    • Search Google Scholar
    • Export Citation
  • 3

    Daniel E, Newell-Price JDC. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndrome. European Journal of Endocrinology 2015 172 R263R280. (https://doi.org/10.1530/EJE-14-1014)

    • Search Google Scholar
    • Export Citation
  • 4

    Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. European Journal of Endocrinology 2015 172 473481. (https://doi.org/10.1530/EJE-14-0913)

    • Search Google Scholar
    • Export Citation
  • 5

    Duggan S. Osilodrostat: first approval. Drugs 2020 80 495500. (https://doi.org/10.1007/s40265-020-01277-0)

  • 6

    Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH & Boscaro M et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. Journal of Clinical Endocrinology and Metabolism 2014 99 13751383. (https://doi.org/10.1210/jc.2013-2117)

    • Search Google Scholar
    • Export Citation
  • 7

    Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T & Hilliard A et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary 2016 19 138148. (https://doi.org/10.1007/s11102-015-0692-z)

    • Search Google Scholar
    • Export Citation
  • 8

    Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, Suzuki A, Sato M, Shimatsu A. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing’s syndrome other than Cushing’s disease. Endocrine Journal 2020 In press. (https://doi.org/10.1507/endocrj.EJ19-0617)

    • Search Google Scholar
    • Export Citation
  • 9

    Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, Libé R, Allolio B, Bertagna X & Bertherat J et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. Journal of Clinical Endocrinology and Metabolism 2013 98 161171. (https://doi.org/10.1210/jc.2012-2851)

    • Search Google Scholar
    • Export Citation
  • 10

    Ménard J, Rigel DF, Watson C, Jeng AY, Fu F, Beil M, Liu J, Chen W, Hu CW & Leung-Chu J et al. Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects. Journal of Translational Medicine 2014 12 340. (https://doi.org/10.1186/s12967-014-0340-9)

    • Search Google Scholar
    • Export Citation
  • 11

    Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, Wass JA, Besser GM. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clinical Endocrinology 1991 35 169178. (https://doi.org/10.1111/j.1365-2265.1991.tb03517.x)

    • Search Google Scholar
    • Export Citation
  • 12

    Kamenický P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M & Baudin E et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 2011 96 27962804. (https://doi.org/10.1210/jc.2011-0536)

    • Search Google Scholar
    • Export Citation
  • 13

    Newell-Price J, Nieman LK, Reincke M, Tabarin A. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of Cushing’s syndrome. European Journal of Endocrinology 2020 183 G1G7. (https://doi.org/10.1530/EJE-20-0352)

    • Search Google Scholar
    • Export Citation